Navigation Links
Reportlinker Adds The Top 10 CMOs in India: Market Dynamics, Competitive Positioning and Trends

NEW YORK, Oct. 19 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

The Top 10 CMOs in India: Market dynamics, competitive positioning and trends

India offers significant cost advantages over mature manufacturing hubs in Europe and North America. Both domestic pharmas and contract manufacturers (CMOs) are moving up the value chain into process development and drug discovery services. Many have evolved into Contract Research and Manufacturing Services (CRAMS) players.

The Top 10 Indian CMOs faced a challenging business environment in the fiscal year, 2010 – most saw revenues contract on the previous year. This report analyzes each of the Top 10 CMOs in turn, reviewing growth strategies and recent deals.

Key Features

  • Overview of the global contract manufacturing market
  • Market dynamics of Indian CMO market
  • Profile of the leading 10 players in Indian CMO/CRAMS market
  • Key contract manufacturing partnerships in the Indian CMO sector
  • Key trends and opportunities in Indian CMO market
  • Major success factors in Indian CRAMS market
  • Strategic growth analysis including SWOT profiles of leading 10 players in Indian CMO market
  • Short profile of other leading players

  • Key Benefits

  • Analyze the competitive positioning and outlook for each of the Top 10 Indian CMOs/CRAMS companies.
  • Develop insights on the Indian CMO market, including market size forecast, and future outlook of global CRAMS industry and opportunities in India.
  • Discover contract manufacturing deals that are shaping the development of the market.
  • Learn the key factors for success in the CMO market.
  • Understand the major issues affecting the Indian CMO industry.
  • Assess the financial performance and growth strategies of leading companies in Indian CMO market.

  • Key findings The global pharmaceutical contract manufacturing market can be categorized into injectables, solid and liquid dosage forms. Solid dosage is the largest segment by revenue, but the injectable segment is expected to show greatest growth.

    Asian CMOs started with large-scale manufacturing for generic and research driven companies are now acquiring assets in the US and Europe to enter the discovery and development segment of the pharmaceutical value chain.

    India, riding on its cost-value proposition comprising low-cost skilled manpower and technical capabilities is strongly positioned to capture a significant portion of the growing CMO market. The CRAMS market will continue to provide high growth opportunity and companies which offer reliable services with a significant value proposition in terms of costs and technology will succeed.

    India has already emerged as one of the leading cost-competitive and quality manufacturing hubs for many global players including big pharma companies. Moreover, the current economic crisis along with the continuous pricing pressure and pro-generic agenda are driving pharma companies to leverage the strengths of Indian pharma manufacturers.

    Drivers of the Indian CMO market include the high number of FDA approved manufacturing facilities, large and growing talent pool and continuing cost advantages. Resistors include intellectual property concerns, competition from China, and safety concerns.

    Key questions answered by this report

  • What are the key trends of Indian contract manufacturing industry?
  • Which companies will drive the future of the Indian CMO market?
  • What are the strengths, weaknesses, threats, and opportunities of the leading CMOs in India?
  • How was the financial performance of leading players in the Indian CMO market affected by the recent economic downturn?
  • Which companies are best positioned to succeed in Indian CMO market in the next five years?
  • How are the growth strategies of leading Indian CMOs such as Jubilant Organosys, Dr. Reddy's, Divis Laboratories, Dishman, Piramal Healthcare, Hikal, Shasun, and Biocon evolving?
  • Which are the key contract manufacturing partnerships that will shape the future of Indian CMO market?

  • Table of ContentsAbout the author 2

    Disclaimer 2

    Executive summary 11

    Industry overview 11

    Jubilant Organosys 11

    Dr. Reddy's 12

    AuroSource 13

    Divis Laboratories 13

    Dishman 14

    Piramal Healthcare 15

    Hikal 15

    Shasun Chemicals and Drugs Limited (SCDL) 16

    Biocon 17

    Suven Life Sciences 17

    Chapter 1 Scope 19

    Scope 19

    Methodology 19

    Chapter 2 Industry overview 20

    Summary 20

    What are CMOs? 21

    Structure of the CMO industry 21

    CMO expansion in Asia 22

    Contract manufacturing and research services in context 23

    Custom synthesis 23

    Contract manufacturing in pharma 24

    Key success factors for CMOs 26

    Value addition to end-users 26

    Scientific skill-set 26

    Respect for intellectual property rights 26

    Cost-effectiveness 26

    Strong relationship with innovators 26

    The Indian CRAMS business 27

    Factors impacting the growth momentum of CRAMS in India 27

    India – a biopharmaceutical manufacturing hub 28

    Regulatory and IP issues 29

    Key contract manufacturing/research deals in India 29

    Future outlook of the global CRAMS industry and opportunities for India 30

    Market dynamics 32

    CRAMS market size and structure 32

    Competitive landscape of the Indian CMO industry 32

    Drivers and resistors of Indian CMOs 34

    Chapter 3 Jubilant Organosys 36

    Summary 36

    Company overview 37

    Business segmentation 38

    R&D focus 39

    Financial performance 40

    Growth strategies 43

    Partnering with pharma and biotech clients 43

    Full service provision 43

    Diversified niche businesses reduce risks 43

    SWOT analysis 45

    Chapter 4 Dr. Reddy's 46

    Summary 46

    Company overview 47

    Business segmentation 48

    R&D focus 48

    Financial performance 49

    Growth strategies 50

    mPEG alcohol manufacturing facility in Mexico 50

    Strategic alliance with GSK for emerging markets outside India 50

    SWOT analysis 51

    Chapter 5 AuroSource 52

    Summary 52

    Company overview 53

    Business segmentation 53

    R&D focus 54

    Financial performance 54

    Growth strategies 55

    Aurobindo's investment in CRAMS business 55

    Diversified contract manufacturing capabilities 55

    SWOT analysis 56

    Chapter 6 Divis Laboratories 57

    Summary 57

    Company overview 58

    Business segmentation 58

    R&D focus 59

    Financial performance 60

    Growth strategies 60

    Innovation driven pharma companies continue to be key clients 60

    Strong chemistry skills and process development capabilities 60

    Generic API business to maintain steady growth 61

    SWOT analysis 62

    Chapter 7 Dishman 63

    Summary 63

    Company overview 64

    Business segmentation 65

    R&D focus 65

    Financial performance 66

    Growth strategies 66

    CRAMS business will continue to dominate 66

    Dishman's Solvay operation rejuvenates with its recent acquisition by Abbott 67

    High number of capacity expansions and state-of-the-art manufacturing facilities 67

    SWOT analysis 68

    Chapter 8 Piramal Healthcare 69

    Summary 69

    Company overview 70

    Business segmentation 71

    R&D focus 71

    Financial performance 72

    Growth strategies 73

    Strong distribution and marketing infrastructure in India 73

    Rationalization of international contract manufacturing unit to increase its efficiency 73

    SWOT analysis 74

    Chapter 9 Hikal 75

    Summary 75

    Company overview 76

    Business segmentation 77

    R&D focus 77

    Financial performance 78

    Growth strategies 78

    Long-term contracts with leading life sciences companies 78

    Expansion of manufacturing base by adding new plants at its FDA site 79

    SWOT analysis 80

    Chapter 10 Shasun Pharmaceuticals Limited 81

    Summary 81

    Company overview 82

    Business segmentation 82

    R&D focus 83

    Financial performance 84

    Growth strategies 85

    Manufacturing higher quantities of existing products 85

    Integrating CRAMS offering across geographies 85

    SWOT analysis 86

    Chapter 11 Biocon 87

    Summary 87

    Company overview 88

    Business segmentation 89

    R&D focus 89

    Financial performance 90

    Growth strategies 90

    Strong manufacturing capabilities in wide range of segments 90

    R&D collaboration with Bristol-Myers Squibb 91

    Biopharmaceutical revenues to maintain steady growth in coming years 91

    SWOT analysis 92

    Chapter 12 Suven Life Sciences 93

    Summary 93

    Company overview 94

    Business segmentation 94

    R&D focus 95

    Financial performance 96

    Growth strategies 96

    Certified facilities to cater for the needs of global pharmaceutical companies 96

    Dedicated pharmaceutical product services in the form of Suven Nishtaa 96

    SWOT analysis 97

    Chapter 13 Other key players 98

    Summary 98

    Lupin (Novodigm) 99

    Company overview 99

    Recent financial performance 99

    Intas 100

    Company overview 100

    Recent financial performance 101

    Ranbaxy (under Daiichi Sankyo) 101

    Company overview 101

    Recent financial performance 102

    Wockhardt 102

    Company overview 103

    Recent financial performance 103

    Strides Arcolab 104

    Company overview 104

    Recent financial performance 104

    Appendix 106

    Glossary 106

    Table of figuresFigure 1: Factors influencing manufacturing outsourcing in India 25

    Figure 2: Drivers and resistors of Indian CMOs 35

    Figure 3: Jubilant Organosys business segmentation 38

    Figure 4: Jubilant Organosys SWOT analysis 45

    Figure 5: Dr. Reddy's business segmentation 48

    Figure 6: Dr. Reddy's SWOT analysis 51

    Figure 7: AuroSource SWOT analysis 56

    Figure 8: Divis Laboratories SWOT analysis 62

    Figure 9: Dishman SWOT analysis 68

    Figure 10: Piramal Healthcare SWOT analysis 74

    Figure 11: Hikal SWOT analysis 80

    Figure 12: Shasun SWOT analysis 86

    Figure 13: Biocon SWOT analysis 92

    Figure 14: Suven SWOT analysis 97

    Table of TablesTable 1: Key contract manufacturing or research deals in India, 2007–10 30

    Table 2: Indian contract manufacturing market size forecast ($bn), 2009–15 32

    Table 3: Leading 10 CMOs/CRAMS players in India, FY 2010 33

    Table 4: Jubilant Organosys snapshot 37

    Table 5: Jubilant Organosys financial performance by segment ($m), FY 2010 41

    Table 6: Jubilant Organosys pharma services financial performance by segment ($m), FY 2010


    Table 7: Jubilant Organosys CRAMS financial performance by segment ($m), FY 2010 42

    Table 8: Dr. Reddy's snapshot 47

    Table 9: Dr. Reddy's financial performance by segment ($m), FY 2010 49

    Table 10: AuroSource snapshot 53

    Table 11: Divis Laboratories snapshot 58

    Table 12: Dishman snapshot 64

    Table 13: Dishman financial performance by segment ($m), FY 2010 66

    Table 14: Piramal Healthcare snapshot 70

    Table 15: Piramal Healthcare financial performance by segment ($m), FY 2010 72

    Table 16: Hikal snapshot 76

    Table 17: Hikal financial performance by segment ($m), FY 2010 78

    Table 18: Shasun Pharmaceuticals Limited snapshot 82

    Table 19: Shasun total sales ($m), FY 2010 84

    Table 20: Shasun financial performance by key segment ($m), FY 2010 84

    Table 21: Biocon snapshot 88

    Table 22: Biocon financial performance by segment ($m), FY 2010 90

    Table 23: Suven Life Sciences snapshot 94

    Table 24: Suven financial performance by segment ($m), FY 2010 96

    Table 25: Lupin (Novodigm) snapshot 99

    Table 26: Intas snapshot 100

    Table 27: Ranbaxy (now Daiichi Sankyo) snapshot 101

    Table 28: Wockhardt snapshot 102

    Table 29: Strides Arcolab snapshot 104

    Table 30: Strides Arcolab financial performance by segment ($m), FY 2010 105

    To order this report:Pharmaceutical Industry: The Top 10 CMOs in India: Market dynamics, competitive positioning and trends

    Pharmaceutical Business News

    More  Market Research Report

    Check our  Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

    SOURCE Reportlinker
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Reportlinker Adds Global Minimally Invasive Surgery Market.(2010 - 2015)
    2. Reportlinker Adds Global Diagnostic ECG Market (2010 - 2015)
    3. Reportlinker Adds Global Wound Care Products Industry
    4. Reportlinker Adds Global Veterinary Vaccines Industry
    5. Reportlinker Adds Global Urological Catheters Industry
    6. Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020
    7. Reportlinker Adds Colorectal Cancer - Brazil, China, India and Russia (BRIC) Drug Drug Forecasts and Treatment Analysis to 2020
    8. Reportlinker Adds Sales Force Effectiveness in Pharmaceuticals - Cost Pressures Increase Pharmaceutical Companies Adoption of New Sales Models and Technologies
    9. Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth
    10. Reportlinker Adds Imaging Diagnostics Market in Poland 2010 - Development Forecasts for 2010-2012
    11. Reportlinker Adds European RIS/PACS Market
    Post Your Comments:
    (Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
    (Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
    (Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
    (Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
    (Date:10/12/2017)... ... 12, 2017 , ... Planet Fitness, one of the largest and fastest growing ... open a flagship location in Covington, LA at 401 N. U.S. Highway 190, in ... to Office Depot in the Holiday Square shopping center. Its location allows it to ...
    (Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
    Breaking Medicine News(10 mins):